You are here: Industry Insights > Orelabrutinib

News List

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma PharmaSources
May 21, 2024
The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.
Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology PharmaSources
April 18, 2024
The study provides compelling evidence for the potential of orelabrutinib as a safe and effective therapy for patients with ITP.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma in China Chunhua Lu
March 13, 2024
BTK inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.
Orelabrutinib: A Novel BTK inhibitor David Orchard-Webb
March 01, 2024
Orelabrutinib, developed by InnoCare Pharma, is an orally bioavailable, second-generation Bruton's tyrosine kinase (BTK) inhibitor.
Chinese BTK Inhibitor Orelabrutinib Gone Global, What Other Drugs Have Been Ok'd Overseas in 2021 PharmaSources/Dopine
July 26, 2021
On July 13, InnoCare Pharma and Biogen made joint announcement that they have entered into an agreement on the license and cooperation of the BTK inhibitor Orelabrutinib.
Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024 PharmaSources
September 14, 2024
Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the European Society for Medical Oncology (ESMO) Congress 2024.
InnoCare Announces Inclusion of Orelabrutinib’s New Indication in China National Reimbursement Drug List 2023 PharmaSources
December 14, 2023
InnoCare Pharma announced today the inclusion of new indication of BTK inhibitor orelabrutinib in the updated National Reimbursement Drug List 2023.
Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology PharmaSources
September 13, 2023
American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone Lymphoma (MZL).
Latest Data of InnoCare’s Orelabrutinib Presented at the 17th International Conference on Malignant Lymphoma (ICML) PharmaSources
June 16, 2023
On June 16, 2023,InnoCare Pharma, a leading biopharmaceutical company, today announced the latest clinical data of its Bruton Tyrosine Kinase inhibitor orelabrutinib at the 17th International Conference on Malignant Lymphoma.
Clinical Study Result of Orelabrutinib in Patients with R/R MCL Published by Blood Advances PharmaSources
May 04, 2023
Blood Advances recently published the clinical study study result of BTK inhibitor orelabrutinib in Relapsed or Refractory Mantle Cell Lymphoma patients.